Evidence map›Paper›PMID 35292490›Full record

ArticleBMJ open2022

Remote data collection speech analysis and prediction of the identification of Alzheimer's disease biomarkers in people at risk for Alzheimer's disease dementia: the Speech on the Phone Assessment (SPeAk) prospective observational study protocol.

Sarah Gregory, Nicklas Linz, Alexandra König, Kai Langel, Hannah Pullen, Saturnino Luz, John Harrison, Craig W Ritchie

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah GregoryEdinburgh Dementia Prevention, Centre for Clinical Brain Sciences, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK Sarah.Gregory@ed.ac.uk.ORCID 0000-0001-9864-8240
Nicklas Linzki elements, ki elements, Saarbrucken, Saarland, Germany.ORCID 0000-0001-5178-3234
Alexandra KönigStars Team, National Institute for Research in Computer Science and Automation, Nice, France.ORCID 0000-0001-9960-9657
Kai LangelJanssen Healthcare Innovation, Beerse, Belgium.
Hannah PullenEdinburgh Dementia Prevention, Centre for Clinical Brain Sciences, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK.ORCID 0000-0002-1475-4941
Saturnino LuzUsher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-8430-7875
John HarrisonMetis Cognition Ltd, Kilmington Common, UK.ORCID 0000-0002-0225-4923
Craig W RitchieEdinburgh Dementia Prevention, Centre for Clinical Brain Sciences, The University of Edinburgh Centre for Clinical Brain Sciences, Edinburgh, UK.ORCID 0000-0002-6202-6906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIdentifying cost-effective, non-invasive biomarkers of Alzheimer's disease (AD) is a clinical and research priority. Speech data are easy to collect, and studies suggest it can identify those with AD. We do not know if speech features can predict AD biomarkers in a preclinical population. METHODS AND ANALYSIS: The Speech on the Phone Assessment (SPeAk) study is a prospective observational study. SPeAk recruits participants aged 50 years and over who have previously completed studies with AD biomarker collection. Participants complete a baseline telephone assessment, including spontaneous speech and cognitive tests. A 3-month visit will repeat the cognitive tests with a conversational artificial intelligence bot. Participants complete acceptability questionnaires after each visit. Participants are randomised to receive their cognitive test results either after each visit or only after they have completed the study. We will combine SPeAK data with AD biomarker data collected in a previous study and analyse for correlations between extracted speech features and AD biomarkers. The outcome of this analysis will inform the development of an algorithm for prediction of AD risk based on speech features. ETHICS AND DISSEMINATION: This study has been approved by the Edinburgh Medical School Research Ethics Committee (REC reference 20-EMREC-007). All participants will provide informed consent before completing any study-related procedures, participants must have capacity to consent to participate in this study. Participants may find the tests, or receiving their scores, causes anxiety or stress. Previous exposure to similar tests may make this more familiar and reduce this anxiety. The study information will include signposting in case of distress. Study results will be disseminated to study participants, presented at conferences and published in a peer reviewed journal. No study participants will be identifiable in the study results.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedArtificial IntelligenceBiomarkersHumansMiddle AgedObservational Studies as TopicRandomized Controlled Trials as TopicSpeechSurveys and QuestionnairesBiomarkersdelirium & cognitive disordersdementiaold age psychiatry

Identifiers

PMID35292490
PMCPMC8928245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.